These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [On the current debate on lowering LDL cholesterol with ezetimibe]. Breuer HW Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008 [No Abstract] [Full Text] [Related]
5. [Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl]. MMW Fortschr Med; 2004 Oct; 146(44):57. PubMed ID: 15566254 [No Abstract] [Full Text] [Related]
6. [Recommended LDL value far lower. How does one achieve this goal?]. Einecke D MMW Fortschr Med; 2004 Mar; 146(13):6. PubMed ID: 15219116 [No Abstract] [Full Text] [Related]
8. [Statins remain the standard. New methods for lipid lowering therapy]. Aumiller J MMW Fortschr Med; 2001 Oct; 143(42):16-7. PubMed ID: 11697281 [No Abstract] [Full Text] [Related]
9. LDL-Cholesterol is the King. Goumas GS Angiology; 2009; 60(3):387-8. PubMed ID: 19497926 [No Abstract] [Full Text] [Related]
10. New developments in pharmacotherapy. Thompson GR Cardiovasc J S Afr; 2004; 15(2):56-8. PubMed ID: 15148538 [No Abstract] [Full Text] [Related]
11. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism]. MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947 [No Abstract] [Full Text] [Related]
12. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals. Hurley DL; Isley WL Mayo Clin Proc; 2005 May; 80(5):585-6. PubMed ID: 15887424 [No Abstract] [Full Text] [Related]
13. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins]. Sudhop T; von Bergmann K MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402 [No Abstract] [Full Text] [Related]
14. [The current debate on lowering LDL cholesterol with ezetimibe]. Erdmann E Dtsch Med Wochenschr; 2010 Sep; 135(36):1742. PubMed ID: 20812160 [No Abstract] [Full Text] [Related]
15. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Bruckert E; Giral P; Tellier P Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406 [No Abstract] [Full Text] [Related]
16. Dyslipidaemia: No limit to the benefits of LDL-cholesterol lowering. Lim GB Nat Rev Cardiol; 2015 Aug; 12(8):444. PubMed ID: 26099842 [No Abstract] [Full Text] [Related]
17. Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT. Jarcho JA; Keaney JF N Engl J Med; 2015 Jun; 372(25):2448-50. PubMed ID: 26039520 [No Abstract] [Full Text] [Related]
18. Drugs for children with hypercholesterolemia: be cautious. Iughetti L J Pediatr Endocrinol Metab; 2009 Jun; 22(6):483-5. PubMed ID: 19694194 [No Abstract] [Full Text] [Related]
19. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study. Pauriah M; Struthers AD; Lang CC Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130 [No Abstract] [Full Text] [Related]
20. Premature release of data from clinical trials of ezetimibe. Califf RM; Harrington RA; Blazing MA N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335 [No Abstract] [Full Text] [Related] [Next] [New Search]